Wind Tre and iliad form Zefiro Net S.r.l., a 50:50 joint venture, to connect the less densely populated areas of Italy.

Watsons opens its 1,000th store in Manila, Philippines, adding to a total of over 8,000 stores
across 15 markets in Asia, Europe and the Middle East.

Hutchison Ports announces a total investment of approximately US$700 million in two Egyptian port projects, including Ain Sokhna Port and B100, a new container terminal in the Port of Alexandria.

Watsons strengthens its sustainability commitment with over 9,000 Sustainable Choices products.

CKHGT and Vodafone Group announce agreements to combine their UK telecommunications businesses. The value-creating transaction is described to be “great for customers, great for the country and great for competition”.

Hutchison Ports and King Salman Energy Park sign a concession agreement to develop a dry port and bonded logistics zone in the Eastern Province of Saudi Arabia.

AS Watson Group and Amorepacific Group sign an agreement to bring a wide range of Korean beauty products and skincare brands to customers in Asia.

The Hong Kong Offshore LNG Terminal, jointly developed by HK Electric and CLP Power, commences commercial operation. The terminal gives both companies direct access to international LNG markets and provides a longterm alternative fuel source to meet the city’s generation needs.

UK Rails’ first refurbished Class 395 Javelin re-enters passenger service with new seats and carpets, USB at-seat power sockets and LED lighting. Energy meters have also been installed to help reduce the energy and environmental impacts of the rail operator, Southeastern.

Australian Gas Networks’ Hydrogen Park South Australia features the largest electrolyser in  operation in Australia. By mid-2023, the number of premises to which blended renewable hydrogen is supplied has increased from 700 homes to nearly 4,000 homes and commercial properties.

CK Life Sciences presents promising preclinical data in liver cancer for its investigational dual-antigen cancer vaccine co-targeting PRAME (preferentially expressed antigen in melanoma) and PD-L1 (programmed deathligand 1) at the 2023 Society for Immunotherapy of Cancer Annual Meeting in San Diego, USA.

HUTCHMED’s in-house discovered drug FRUZAQLA™ (fruquintinib), for the treatment of colorectal cancer, is the company’s first US FDA approved medicine.

Hutchison Telecommunications Hong Kong Holdings upgrades its 5G sea coverage in  multiple hotspots in Hong Kong by deploying advanced hardware and software technologies  in the 700 MHz band of spectrum.

HUTCHMED’s new flagship manufacturing facility in Shanghai, China, completes construction and commences operations.